Delving into the Latest Updates on Tamibarotene with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Retinobenzoic acid, Tamibaro, Tamibarotene (JAN/INN)

+ [18]

Target

RARα

Action

agonists

Mechanism

RARα agonists(Retinoic acid receptor alpha agonists)

Therapeutic Areas

NeoplasmsHemic and Lymphatic DiseasesOther Diseases+ [2]

Active Indication

Acute Promyelocytic LeukemiaLeukemiaPolycystic Kidney, Autosomal Dominant

Inactive Indication

Advanced Hepatocellular CarcinomaAdvanced Lung Non-Small Cell CarcinomaBreast Cancer+ [9]

Originator Organization

Nippon Shinyaku Co., Ltd.

Active Organization

Rege Nephro Co. Ltd.

Toko Pharmaceutical Industrial Co. Ltd.

Inactive Organization

LadRx Corp.

Syros Pharmaceuticals, Inc.

R&R, Inc.

+ [1]

License Organization

RaQualia Pharma, Inc.

Syros Pharmaceuticals, Inc.

QIAGEN NV

+ [2]

Drug Highest PhaseApproved

First Approval Date

Japan (11 Apr 2005),

Acute Promyelocytic Leukemia

RegulationFast Track (United States), Orphan Drug (United States), Orphan Drug (European Union), Orphan Drug (Japan)

Login to view timeline

Structure/Sequence

Molecular FormulaC22H25NO3

InChIKeyMUTNCGKQJGXKEM-UHFFFAOYSA-N

CAS Registry94497-51-5

【Treatment of Urothelial Carcinoma】 Treatment for urothelial carcinoma includes surgery, chemotherapy (anticancer drugs), and radiation therapy. Chemotherapy is generally used when metastasis has already occurred at diagnosis and surgery is not curative (metastatic urothelial carcinoma) or when the cancer recurs after local therapy such as surgery or radiation therapy (recurrent urothelial carcinoma).
Although there are several recommended treatments for urothelial carcinoma, the options are often limited by side effects and other factors, and these treatments may not be fully effective. Therefore, the development of safer and more effective treatments is desired.
【About the Drugs to be Used in this Clinical Trial】 In this clinical trial, the investigational drug MIKE-1 will be used in combination with nivolumab plus GC (cisplatin gemcitabine), one of the recommended chemotherapy regimens, and subsequently with nivolumab monotherapy for patients with unresectable metastatic or recurrent urothelial cancer. Nivolumab, cisplatin, and gemcitabine are injectable (intravenous infusion), while MIKE-1 is oral.
【Purpose of the Clinical Trial】 The purpose of this clinical trial is to evaluate the efficacy (how much the cancer shrinks or slows down) and safety of the investigational drug MIKE-1 in combination with nivolumab and gemcitabine and cisplatin therapy in patients with untreated unresectable or recurrent urothelial cancer.

Start Date01 May 2025

Sponsor / Collaborator

Nagoya University

[+5]

100 Clinical Results associated with Tamibarotene

Login to view more data

100 Translational Medicine associated with Tamibarotene

Login to view more data

100 Patents (Medical) associated with Tamibarotene

Login to view more data

340

Literatures (Medical) associated with Tamibarotene

01 Nov 2026·Blood neoplasia

Tamibarotene with venetoclax and azacitidine in RARA+ acute myeloid leukemia: results from the SY-1425-202 study

Article

Author: Kambhampati, Suman ; Pollyea, Daniel ; Pigneux, Arnaud ; Kelly, Michael ; Ball, Brian ; Peterlin, Pierre ; Feld, Jonathan ; Fenaux, Pierre ; Chantepie, Sylvain ; McMahon, Christine ; Heiblig, Mael ; Braun, Thorsten ; Torregrosa-Diaz, Jose ; Solh, Melhem ; Robin, Jean-Baptiste ; Roth, David ; Stein, Eytan ; de Botton, Stephane ; Dugan, James ; Gourin, Marie-Pierre ; Schiller, Gary ; Cluzeau, Thomas ; Borate, Uma ; Eghtedar, Alireza

RARA overexpression defines a molecularly distinct subset of acute myeloid leukemia (AML). Tamibarotene, an oral selective RARA agonist, synergizes with azacitidine (AZA) but its addition to venetoclax (VEN) with AZA has not been assessed. SY-1425-202 was a multicenter, open-label, randomized study evaluating tamibarotene combined to VEN/AZA (TAMI/VEN/AZA) vs VEN/AZA alone in newly diagnosed RARA-positive, unfit AML. Part 1 assessed the safety of TAMI/VEN/AZA, part 2 randomized participants to TAMI/VEN/AZA vs VEN/AZA, and part 3 explored salvage therapy with TAMI/VEN/AZA after VEN/AZA failure in part 2. TAMI 6 mg twice daily was administered. Randomization occurred after confirmation of RARA positivity by cycle 1, day 8. The primary end point was complete remission (CR) + CR with incomplete hematologic recovery (CRi) in part 2 and part 3, and safety in part 1. In part 1 (n=10), overall response rate (ORR) was 77.8% (5 CR, 2 CRi). In part 2 (n=51), CR/CRi was 60.0% for TAMI/VEN/AZA and 69.2% for VEN/AZA. Median CR/CRi duration was 293 vs 253 days. ORR was 80.0% vs 73.1%, respectively. In part 3, 2 of 5 patients responded (CR, morphologically leukemia-free state). Grade ≥3 treatment-emergent adverse event occurred in 76% of patients. Deaths were attributed mainly to disease progression or known complications of therapy; none were attributed to TAMI. The study met prespecified futility criteria and was discontinued early. The addition of TAMI to VEN/AZA was tolerable but did not improve efficacy over VEN/AZA. These results did not demonstrate clinical benefit of TAMI in the frontline unfit RARA-positive AML setting receiving VEN/AZA. This trial was registered at www.clinicaltrials.gov as #NCT04905407.

15 Sep 2026·FASEB JOURNAL

Transcriptomic Signatures of Microglial Phagocytosis Reveal Diagnostic Markers and Immune Landscape in Alzheimer's Disease

Article

Author: Chang, Huimin ; Yang, Xiaojun ; Han, Yanqing ; Liu, Yun

ABSTRACT:

The core pathological features of Alzheimer's disease (AD) include Aβ plaques and neurofibrillary tangles, which collectively drive the neurodegenerative process. Meanwhile, the phagocytic function of microglia plays a dual role in AD: it attempts to clear pathological proteins such as Aβ, but its chronic activation may also exacerbate neuroinflammation and synaptic damage. This study integrated microarray data from AD cohorts in the Gene Expression Omnibus (GEO) database. Through differential expression analysis, protein–protein interaction network construction, and three machine learning algorithms (Least Absolute Shrinkage and Selection Operator, Support Vector Machine—Recursive Feature Elimination, and Extreme Gradient Boosting), key microglial phagocytosis‐related signature genes were identified. Diagnostic models were subsequently developed and validated, with further investigation of immune infiltration patterns, regulatory networks, and molecular subtypes. Based on comprehensive analysis, this study identified five core signature genes (HLA‐DPA1, IL4R, ITGAM, SPP1, TNFRSF1B) that form a highly accurate diagnostic model validated in independent cohorts. Immune infiltration analysis revealed significant increases in neutrophils and M2 macrophages in AD brains, with these genes showing strong correlations with immune cell abundance. The study further identified two molecular subtypes with distinct immune features, constructed regulatory networks, and predicted potential therapeutics including Tamibarotene. By integrating transcriptomics and machine learning, this study identifies key molecular features of microglial phagocytosis in AD, providing a novel diagnostic framework and insights into the immune mechanisms of the disease.

21 Jul 2026·Current Neuropharmacology

Integrative Multi-Omics and Mendelian Randomization Analysis Identify Core Genes and Potent Drug Targets for Insomnia

Article

Author: Shi, Wenqing ; A., Yemen ; Wu, Zhenghua ; Zhao, Wenjuan ; Wu, Dongying ; Liu, Chenxi ; Jiang, Xinhui ; Lou, Yuefen ; Fan, Guorong

Introduction::

Insomnia is a common clinical sleep disorder, for which current medications only relieve symptoms symptomatically and highly specific therapeutic targets are limited. This study integrates multi-omics analysis and machine learning to screen and identify novel, safe, and efficient potential therapeutic targets for insomnia, thereby providing new insights for its targeted drug development and precision diagnosis and treatment.

Methods::

We intersected a druggable gene set with blood, brain, and plasma Quantitative Trait Loci (QTL) data, using insomnia and its comorbidities as Genome-Wide Association Study (GWAS) outcomes. Two-sample Mendelian randomization (MR) analysis was used to assess causality, followed by sensitivity testing. The Gene Expression Omnibus (GEO) dataset GSE208668 was used for differential expression analysis and Weighted Gene Co-expression Network Analysis (WGCNA). Cross-validation and machine learning (LASSO regression and random forests) were employed to screen key hub genes and evaluate their diagnostic efficacy. Summary-data-based Mendelian Randomization (SMR), colocalization, and immune infiltration analyses were performed, and potential drugs were predicted via databases and molecular docking simulations.

Results::

Through multi-omics analyses including Mendelian randomization, transcriptome profiling and WGCNA, we identified 10 candidate genes, which were further refined by machine learning to five key hub genes: HLA-G, S1PR1, LGALS3, VIM, and PIK3CG. These genes were upregulated in insomnia patients and had high diagnostic AUC values. They showed extensive genetic associations with the risk of comorbidities such as depression, anxiety, hypertension, and diabetes. SMR and colocalization analyses provided convergent suggestive causal evidence for HLA-G, while the remaining four genes were supported as candidate targets rather than causal drivers. Immune infiltration analysis showed that key genes were associated with altered immune cell subsets. Drug prediction screened potential intervention compounds like decitabine and tamibarotene.

Discussion::

These findings provide robust evidence for novel druggable targets in insomnia, which exert regulatory effects via immune-inflammatory pathways and link insomnia to comorbidity risks. Their diagnostic potential and functional implications further underscore their translational value for clinical application and drug development, but all conclusions remain preliminary due to lack of independent validation.

Conclusion::

This study identified five core genes, among which HLA-G shows suggestive causal links to insomnia, while the others are supported as promising candidate targets. They show promising diagnostic and drug development value, providing insights into insomnia pathogenesis and a theoretical basis for novel biomarkers and targeted therapies.

97

News (Medical) associated with Tamibarotene

24 Jul 2026

·www.prnewswire.com

Rege Nephro Secures approximately US$10.6 Million to Advance RN-014 Toward Commercialization

Financing will support development of RN-014 and RN-032 and continued expansion of the company's kidney disease pipeline July 21, 2026 -- Rege Nephro Co., Ltd. ("Rege Nephro"), a clinical-stage biotechnology company focused on iPS cell-based kidney regenerative medicine and drug discovery, today announced the closing of a financing round totaling approximately US$10.6 million through the issuance of J-KISS (Japan-Keep It Simple Security) share acquisition rights. The proceeds are expected to support commercialization activities for RN-014, the company's lead candidate for autosomal dominant polycystic kidney disease (ADPKD), advance its iPS cell-derived regenerative medicine program RN-032, and fund continued research and development activities. The financing is intended to support the company's growth through its anticipated Series C financing and beyond. Rege Nephro is dedicated to developing innovative therapies and medical technologies for patients with kidney diseases who currently have limited treatment options. The company's lead program, RN-014, recently reached LPLV (Last Patient Last Visit) in its Phase 2a clinical trial, marking an important milestone. RN-014 is a small-molecule therapeutic candidate identified through screening using an iPS cell-derived ADPKD disease model, and analysis of Phase 2a clinical trial data is currently underway. In addition, RN-032, an iPS cell-derived regenerative medicine program based on renal nephron progenitor cells, has completed process development in preparation for nonclinical studies and is progressing to the next stage. The financing will support continued advancement of these core programs while strengthening the company's long-term growth strategy. The capital raised will be allocated across four key priorities: 1. RN-014 Commercialization and Global Licensing Activities Building on insights generated from the Phase 2a clinical trial, Rege Nephro plans to pursue global licensing and partnering opportunities for RN-014 while continuing development activities aimed at further evaluating the program's therapeutic potential. 2. Supporting Nonclinical Development of RN-032 Following the completion of process development for RN-032, the company will advance RN-032 into nonclinical studies to establish the foundation for future clinical trials. 3. Expanding Discovery Research and Kidney Regeneration Programs The company will continue to invest in discovery and translational research, including next-generation kidney regeneration technologies and future pipeline candidates. Rege Nephro ultimately aims to develop therapies that improve outcomes and quality of life for patients with kidney disease while reducing progression to kidney failure. 4. Strengthening Organizational Capabilities To support continued growth, Rege Nephro plans to expand its team by recruiting scientific, clinical development, and business development professionals with specialized expertise. Through this financing, Rege Nephro seeks to advance its pipeline while strengthening the operational foundation required to support future growth and long-term value creation. "This funding round marks an important milestone as we advance RN-014 toward commercialization and accelerate development of RN-032," said Akifumi Morinaka, Representative Director and CEO of Rege Nephro. "I would like to express my sincere gratitude to our investors for their support and confidence in our vision and progress. With RN-014 having completed its Phase 2a clinical trial and RN-032 advancing toward its next stage of development, we believe the company is well positioned for continued growth. We remain committed to addressing unmet medical needs in kidney disease through innovative medicines and regenerative therapies based on iPS cell technology." Rege Nephro Co., Ltd. is a clinical-stage biotechnology company that leverages scientific discoveries originating from the research of Professor Kenji Osafune at Kyoto University's Center for iPS Cell Research and Application (CiRA). The company is developing innovative therapies for kidney diseases based on iPS cell technology, with the goal of expanding treatment options for patients with serious and difficult-to-treat conditions. The content above comes from the network. if any infringement, please contact us to modify.

Financing

17 Apr 2025

·endpts.com

Bayer opens $44M US expansion; Meribel CDMO launches in Europe

Welcome to Endpoints News’ manufacturing briefs, where we bring you essential news on new builds, collaborations, recalls and more. Bayer has opened its $44 million 70,000-square-foot expansion at its Myerstown, PA, facility, the company said Wednesday. The site manufactures products for Bayer’s consumer health business. A new mid-size CDMO called Meribel Pharma Solutions launched on Tuesday, according to a release on the same day. The new company will operate out of 10 manufacturing sites, seven of which it bought from Recipharm last year, and three research and development facilities in Europe. Ginkgo Bioworks has secured a $29 million two-year contract with Advanced Research Projects Agency for Health along with other companies including Tritica Biosciences, US Pharmacopeia, On Demand Pharmaceuticals and Isolere Bio by Donaldson. The project is intended to establish a new manufacturing process for APIs using wheat germ cell-free expression tech, according to a release on April 10. CDMO Chime Biologics has partnered with Polpharma Biologics to manufacture an unnamed biosimilar, according to a Wednesday release. Cell therapy biotech Atelerix has teamed up with China-based logistics company MineBio, which will distribute Atelerix’s products in China, the companies said Tuesday. FesariusTherapeutics has partnered with Regenity Biosciences who will manufacture FesariusTherapeutics’ collagen-based dermal regeneration templates used to treat patients with wounds, according to a Thursday press release. Renal disease-focused Rege Nephro has acquired clinical and non-clinical assets related to the chemical tamibarotene from Syros Pharmaceuticals, the company said Tuesday. The deal closed on Feb. 26. Clinical-stage INmune Bio has partnered with UK-based CGT Catapult to establish commercial manufacturing for its cell therapy technologies, according to a Monday release. Kyowa Kirin has completed the construction of its new 16.8 billion Japanese yen ($118 million) drug substance manufacturing site in Takasaki, Japan, the company said on Apr. 11.

Cell Therapy

15 Apr 2025

·www.prnewswire.com

Rege Nephro Acquires Tamibarotene-Related Assets from Syros Pharmaceuticals for U.S. Clinical Trials

KYOTO, Japan, April 15, 2025 /PRNewswire/ -- Rege Nephro Co., Ltd. (Headquarter: Kyoto, Japan; Chief Executive Officer: Akifumi Morinaka) has announced that it has successfully acquired Tamibarotene-related clinical and non-clinical assets from Syros Pharmaceuticals, Inc. (Headquarters: Boston, MA; NASDAQ:SYRS), through a mutual agreement. The acquisition was completed on February 26, 2025. Tamibarotene (RN-014) is a retinoic acid receptor agonist for which Rege Nephro is currently conducting a Phase 2 clinical trial in Japan in autosomal dominant polycystic kidney disease (ADPKD). Rege Nephro expects to initiate clinical trials in the United States, after confirming the efficacy and safety in Japan. Syros Pharmaceuticals has previously carried out a Phase 3 clinical trial of Tamibarotene for indications including myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). This acquisition, encompassing their clinical and non-clinical data including human safety study for New Drug Application (NDA), contracts with a contract manufacturing organization (CMO), and Tamibarotene active pharmaceutical ingredient (API) and drug products, is expected to enhance Rege Nephro's capabilities and streamline operations for its clinical trial operations in the United States. About Rege Nephro: Rege Nephro, founded in 2019, is a clinical-stage biotech company leveraging technology based on research of Prof. Kenji Osafune, deputy director of the Center for iPS Cell Research and Application (CiRA), Kyoto University. The company is developing therapeutics and cell therapy for diseases related to the kidneys, liver, and pancreas. For more information, please visit . About RN-014: RN-014 is a therapeutic candidate for autosomal dominant polycystic kidney disease (ADPKD). It is a retinoic acid receptor (RAR) agonist expected to suppress cyst formation and improve renal function. Rege Nephro initiated a Phase 2 clinical trial in December 2023, and enrollment for the second stage has now been completed. To date, no significant safety concerns have arisen and preliminary efficacy has been demonstrated. SOURCE Rege Nephro Co., Ltd. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Phase 2Cell TherapyAcquisitionPhase 3Phase 1

100 Deals associated with Tamibarotene

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D01418	Tamibarotene	L01X	DB04942

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Acute Promyelocytic Leukemia	Japan	Toko Pharmaceutical Industrial Co. Ltd.	11 Apr 2005

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
RARA positive Myelodysplastic Syndrome	Phase 3	United States	Syros Pharmaceuticals, Inc.	08 Feb 2021
RARA positive Myelodysplastic Syndrome	Phase 3	Austria	Syros Pharmaceuticals, Inc.	08 Feb 2021
RARA positive Myelodysplastic Syndrome	Phase 3	Belgium	Syros Pharmaceuticals, Inc.	08 Feb 2021
RARA positive Myelodysplastic Syndrome	Phase 3	Canada	Syros Pharmaceuticals, Inc.	08 Feb 2021
RARA positive Myelodysplastic Syndrome	Phase 3	Czechia	Syros Pharmaceuticals, Inc.	08 Feb 2021
RARA positive Myelodysplastic Syndrome	Phase 3	France	Syros Pharmaceuticals, Inc.	08 Feb 2021
RARA positive Myelodysplastic Syndrome	Phase 3	Germany	Syros Pharmaceuticals, Inc.	08 Feb 2021
RARA positive Myelodysplastic Syndrome	Phase 3	Hungary	Syros Pharmaceuticals, Inc.	08 Feb 2021
RARA positive Myelodysplastic Syndrome	Phase 3	Israel	Syros Pharmaceuticals, Inc.	08 Feb 2021
RARA positive Myelodysplastic Syndrome	Phase 3	Italy	Syros Pharmaceuticals, Inc.	08 Feb 2021

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04905407 (SY-1425-202, Pubmed \| Blood Neoplasia)	Phase 1	RARA positive Acute Myeloid Leukemia First line RARA positive	62	Tamibarotene+Venetoclax+Azacitidine	pcykszfvbx(uvvulojczz) = haguvwtxau dsriyxaqgx (qsmowlzelz ) View more	Negative	01 Nov 2026
				Venetoclax+Azacitidine	pcykszfvbx(uvvulojczz) = lponojoxrw dsriyxaqgx (qsmowlzelz ) View more
JPRN-jRCTs041190101 (APL219R, EHA2026)	Phase 2	CD33-positive	39	Tamibarotene+Arsenic trioxide+Gemtuzumab ozogamicin	bqbfoxymxt(rpdjhgqulj) = rppbquqwke ztmajvebqm (vwuijnijqy ) View more	Positive	12 May 2026
NCT04797780 (SELECT-MDS-1, CTgov)	Phase 3	RARA positive Myelodysplastic Syndrome	246	Tamibarotene+Azacitidine (Tamibarotene + Azacitidine)	snebhtxedw = juoiilukff xbseqbttpz (egezcsjngu, uqwofxapef - vrnnkvvriq) View more	-	10 Apr 2025
				Placebo+Azacitidine (Tamibarotene Matched Placebo + Azacitidine)	snebhtxedw = wssxrsrwwn xbseqbttpz (egezcsjngu, zcskgadzzy - efvgjsrxpx) View more
NCT04905407 (SY-1425-202 \| AML-347 SELECT-AML-1 \| SELECT AML-1 \| SELECT-AML-1, CTgov)	Phase 2	RARA positive Acute Myeloid Leukemia	66	Tamibarotene+Venetoclax+Azacitidine (Part 1: Tamibarotene/Venetoclax/Azacitidine)	djbiekwvkq = upxtgaztbl mvrokbdsbt (syqrjlcwsz, lcoqulysmd - ileghepasi) View more	-	24 Feb 2025
				Tamibarotene+Venetoclax+Azacitidine (Part 2: Tamibarotene/Venetoclax/Azacitidine)	oxnistfttk = yroxizxgww evncpkuecz (chodkuurnu, zwylpxcjck - tzrtquuwjd) View more
NCT02807558 (CTgov)	Phase 2	Acute Myeloid Leukemia \| Myelodysplastic Syndromes	155	Tamibarotene (R/R Non-APL AML or R/R HR-MDS: Tamibarotene Monotherapy)	syxaomntyu = rqqmzpswba peapakyczn (bzkyagvgkl, oqsxdqbdpf - pztogdvths) View more	-	13 Dec 2024
				Tamibarotene (Newly Diagnosed Non-APL AML: Tamibarotene Monotherapy)	syxaomntyu = dfcrjlaewf peapakyczn (bzkyagvgkl, fijaejfrkv - ijeacnpxia) View more
NCT04797780 (SELECT-MDS-1, Company_Website) Manual	Phase 3	High Risk Myelodysplastic Syndrome	190	Tamibarotene in combination with azacitidine	qlptmcuruw(zicaruelav) = ctdwgmosdm mnsowckeek (lqtoztorbg, 16.7 - 32.2) Not Met	Negative	12 Nov 2024
				Placebo and azacitidine	qlptmcuruw(zicaruelav) = athfsbxglj mnsowckeek (lqtoztorbg, 10.1 - 30.5) Not Met
NCT04905407 (AML-347 SELECT-AML-1, SOHO2024)	Phase 2	RARA positive Acute Myeloid Leukemia RARA overexpression	80	Tamibarotene 6 mg PO BID + Venetoclax-Azacitidine	nhswihxheq(wwqtjyjpde) = hggobeywip xoxobrowgc (dgotiacpqh ) View more	Positive	04 Sep 2024
				Venetoclax-Azacitidine	nhswihxheq(wwqtjyjpde) = spjtbybluy xoxobrowgc (dgotiacpqh ) View more
NCT04905407 (SELECT-AML-1, NEWS) Manual	Phase 2	RARA positive Acute Myeloid Leukemia RARA	19	tamibarotene+venetoclax+azacitidine	pxxrbrsxps(wmeziqohqr) = nmrjxshuyl wprrerhths (kzrykuilsx ) View more	Positive	07 Dec 2023
				venetoclax+azacitidin	pxxrbrsxps(wmeziqohqr) = qxpgttwvdt wprrerhths (kzrykuilsx ) View more
NCT02807558 (Pubmed)	Phase 2	Acute Myeloid Leukemia	51	Tamibarotene plus azacitidine	kgzpcscjob(mogehhbggf) = hematologic AEs were comparable to single agent azacitidine, demonstrating that there was no additional myelosuppression when tamibarotene was combined with azacitidine forqxucwuu (sjzmaberfd ) View more	-	07 Dec 2022
NCT04905407 (SELECT-AML-1, ASH 12022 \| ASH 22022) Manual	Phase 2	RARA positive Acute Myeloid Leukemia First line RARA	6	Venetoclax+Azacitidine+Tamibarotene	hdayqbbvin(iaiodywklz) = occurring in more than one patient was febrile neutropenia jxwgisyxep (sphsbaowzz ) View more	Positive	15 Nov 2022
				Venetoclax+Azacitidine